New pill combo aims to tackle Hard-to-Treat breast cancer

NCT ID NCT07173556

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a new drug called QLC1401, taken as a tablet, combined with either CDK4/6 inhibitors or mTOR inhibitors for people with ER+/HER2- advanced breast cancer. The trial has two parts: first, finding the safest dose, then checking how well it works. About 96 participants will join to see if the combination can shrink tumors and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLC1401 tablets combined with CDK4/6 inhibitors (palbociclib, abemaciclib, ribociclib) or mTOR inhibitors (everolimus)
What this could lead to: If successful, this could offer a new treatment option for people with ER+/HER2- advanced breast cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 96 participants, so results may not apply to all patients. The combination may cause side effects or fail to shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.